Literature DB >> 10996424

Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44 cases.

A Carretta1, G L Ceresoli, G Arrigoni, B Canneto, M Reni, C Cigala, P Zannini.   

Abstract

Neuroendocrine tumors of the lung (NTL) are a distinct subset of tumors with a wide range of histological patterns and clinical behavior. Controversy still exists as to the ideal diagnostic and therapeutic approach to these neoplasms. A series of 44 consecutive NTL patients operated on at our Institution was retrospectively reviewed in order to critically analyze the diagnostic and therapeutic management. A preoperative diagnosis was obtained in 11 patients (25%). All patients underwent an anatomical surgical resection with lymphoadenectomy. Pathological diagnosis was typical carcinoid (TC) tumor in 36 cases, atypical carcinoid (AC) in three and large-cell neuroendocrine carcinoma (LCNEC) in five. One patient had preoperative chemotherapy. Node-positive patients received postoperative radiotherapy on the mediastinal area. Median follow-up time was 40 months for TC and 51.5 months for AC/LCNEC. Recurrence of disease was observed in three patients with TC and in two with AC/LCNEC. Actuarial 5-year survival was 93% for TC and 70% for AC/LCNEC. Survival was not influenced by tumor size, while lymph node metastases were associated with a worse prognosis. However, due to the limited number of patients, no statistical significance was observed. In conclusion, our study confirms findings in the literature showing that TC and AC/LCNEC are clinically different, and that a differential preoperative diagnosis and treatment is necessary. Although the results of new diagnostic techniques such as octreotide scintigraphy are encouraging, they need to be validated in a larger number of patients. Surgery, with anatomical resection and lymphoadenectomy, remains the treatment of choice in all these tumors. Laser treatment should be considered only as a palliative procedure or as a complementary technique to surgery. The role of adjuvant treatments in AC and LCNEC is uncertain and should be evaluated in larger trials. The prognostic role of biological factors such as cytometry and genetic markers requires further investigation before any definitive conclusions can be drawn.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10996424     DOI: 10.1016/s0169-5002(00)00119-7

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  14 in total

1.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

2.  Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.

Authors:  Toshiyuki Kozuki; Nobukazu Fujimoto; Hiroshi Ueoka; Katsuyuki Kiura; Keiichi Fujiwara; Katsuhiko Shiomi; Koichi Mizobuchi; Masahiro Tabata; Shuji Hamazaki; Mitsune Tanimoto
Journal:  J Cancer Res Clin Oncol       Date:  2004-11-05       Impact factor: 4.553

3.  Specific expression of ZO-1 and N-cadherin in rosette structures of various tumors: possible recapitulation of neural tube formation in embryogenesis and utility as a potentially novel immunohistochemical marker of rosette formation in pulmonary neuroendocrine tumors.

Authors:  Kaishi Satomi; Yukio Morishita; Shingo Sakashita; Yuzuru Kondou; Shuichiroh Furuya; Yuko Minami; Masayuki Noguchi
Journal:  Virchows Arch       Date:  2011-07-23       Impact factor: 4.064

4.  Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung.

Authors:  Daisuke Okada; Masashi Kawamoto; Kiyoshi Koizumi; Shigeo Tanaka; Yuh Fukuda
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-07

Review 5.  Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations.

Authors:  Edward M Wolin
Journal:  Oncologist       Date:  2015-08-25

6.  Carcinoid lung tumors: long-term results from 111 resections.

Authors:  Thomas Kyriss; Sibylle Maier; Stefanie Veit; Peter Fritz; Heikki Toomes; Godehard Friedel
Journal:  Thorac Surg Sci       Date:  2006-09-04

7.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).

Authors:  John K Ramage; A Ahmed; J Ardill; N Bax; D J Breen; M E Caplin; P Corrie; J Davar; A H Davies; V Lewington; T Meyer; J Newell-Price; G Poston; N Reed; A Rockall; W Steward; R V Thakker; C Toubanakis; J Valle; C Verbeke; A B Grossman
Journal:  Gut       Date:  2011-11-03       Impact factor: 23.059

8.  Neuroendocrine differentiation and neuroendocrine morphology as two different patterns in large-cell bronchial carcinomas: outcome after complete resection.

Authors:  Wolfgang Jungraithmayr; Gian Kayser; Bernward Passlick; Stephan Eggeling
Journal:  World J Surg Oncol       Date:  2006-09-05       Impact factor: 2.754

9.  Carcinoid tumours of the lung and the 'PEPPS' approach: evaluation of preoperative bronchoscopic tumour debulking as preparation for subsequent parenchyma-sparing surgery.

Authors:  Michael Neuberger; Alexander Hapfelmeier; Michael Schmidt; Wolfgang Gesierich; Frank Reichenberger; Alicia Morresi-Hauf; Rudolf A Hatz; Michael Lindner
Journal:  BMJ Open Respir Res       Date:  2015-07-15

10.  Outcomes after surgical resection of pulmonary carcinoid tumors.

Authors:  Ikenna C Okereke; Angela M Taber; Rogers C Griffith; Thomas T Ng
Journal:  J Cardiothorac Surg       Date:  2016-03-02       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.